|Day Low/High||233.80 / 239.47|
|52 Wk Low/High||217.10 / 468.55|
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
Besides Tesla, Twitter and Biogen make good candidates.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.
Deal rumors are deflating, but a takeover bid could reward holdouts.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.
The companies were also the subject of merger rumors back in April.
The drug stock has soared sharply higher in recent weeks; how it behaves on a pullback will be key.
Shares of Biogen and Ionis Pharmaceuticals were higher Monday after announcing that their treatment for a rare, children's spine disorder had some positive results.
That may be the best way to get through the notorious month of August.
Stocks break free of range-bound trading by late morning as gains in biotech help to offset losses in energy.
The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...
The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...
Quarterly reports continued to come in at breakneck speed with some of the key highlights including American Express, eBay, General Motors, Southwest Airlines, and Biogen.
Biogen shares could be on a turnaround trajectory after a year of disappointments.
General Motors crushed Wall Street earnings estimates before the opening bell.
For the week of July 18, the earnings parade continues, with dozens of major companies reporting financial results.
The charitable trust sold out of its position in Biogen while also trimming its holdings in Target.
Any turn in the fundamentals or sentiment easily can send these shares trading much higher from here.
Action Alerts PLUS holdings Apple, Biogen and Costco make moves in the market with Brexit concerns, drug prospects and overall vulnerability.
But above all, know your time frame.